Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Design Therapeutics (DSGN) EBITDA (2020 - 2026)

Design Therapeutics' EBITDA history spans 2 years, with the latest figure at -$11.3 million for Q4 2021.

  • On a quarterly basis, EBITDA fell 192.8% to -$11.3 million in Q4 2021 year-over-year; TTM through Dec 2021 was -$35.9 million, a 331.37% decrease, with the full-year FY2025 number at -$79.5 million, down 27.39% from a year prior.
  • EBITDA hit -$11.3 million in Q4 2021 for Design Therapeutics, roughly flat from -$11.3 million in the prior quarter.
  • Over the last five years, EBITDA for DSGN hit a ceiling of -$623000.0 in Q1 2020 and a floor of -$11.3 million in Q3 2021.